Optimal Stent Duration After Ureteroscopy
Launched by MAYO CLINIC · Sep 13, 2023
Trial Information
Current as of November 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is testing whether removing a ureteral stent sooner (3–5 days after ureteroscopy) is as safe and might cause fewer urinary symptoms than removing it later (7–9 days). Participants are adults having one-side (unilateral) stone treatment with uncomplicated ureteroscopy. They are randomly assigned to the shorter or longer stent duration and then complete questionnaires to track urinary symptoms, pain, and overall quality of life, with additional checks for any complications within 30 days. Researchers use these patient reports to see if earlier stent removal helps patients feel better without increasing risk.
To be eligible, people should be 18 or older and undergoing unilateral stone treatment with an uncomplicated ureteroscopy, using semi-rigid or flexible instruments. Key exclusions include pregnancy, having a stent or nephrostomy before surgery, more complex procedures, active infection or frequent UTIs, no visible stones, kidney transplant, or unusual kidney anatomy. The trial involves many centers in the United States and Canada and is currently enrolling by invitation, with results expected after completion in 2025.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Participants undergoing unilateral stone treatment. Patients may have stones present bilaterally, but must only be having unilateral intervention.
- • The ureteroscopy must be uncomplicated
- • Patients undergoing semi-rigid ureteroscopy only, flexible ureteroscopy only, or a combination
- • Exclusion Criteria
- • Pregnancy
- • A stent or nephrostomy tube placed prior to surgery
- • Complex ureteroscopy - ureteral injury, ureteral perforation, ureteral stricture, impacted stone
- • Infection or struvite stones
- • Recurrent Urinary Tract Infection (UTI): 2 culture proven UTI in 6 months or 3 culture proven UTIs in one year
- • No stone evident on ureteroscopic evaluation of ureter or kidney
- • Transplant kidney
- • Variant anatomy (horseshoe, pelvic kidney)
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Chapel Hill, North Carolina, United States
Cleveland, Ohio, United States
Nashville, Tennessee, United States
San Diego, California, United States
Rochester, Minnesota, United States
Phoenix, Arizona, United States
San Diego, California, United States
Baltimore, Maryland, United States
Bronx, New York, United States
Tucson, Arizona, United States
Vancouver, British Columbia, Canada
Montréal, Quebec, Canada
Patients applied
Trial Officials
Karen Stern, MD
Principal Investigator
Mayo Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported